21 What surprised Julian most about the initial VR therapy data?
A The high dropout rate.
B The positive response from elderly patients.
C The frequency of technical glitches.
22 Professor Vance is concerned that the Mind-Sphere software
A is too expensive for clinical use.
B lacks customizable environments.
C overstimulates the users.
23 How will Julian address the ‘cybersickness’ issue in his report?
A By excluding affected participants from the data.
B By comparing it to traditional motion sickness.
C By suggesting shorter VR session times.
24 What does Julian plan to do next week?
A Interview Dr. Aris Thorne.
B Analyze the heart rate monitor data.
C Finalize the methodology section.
25 Regarding the final presentation, Professor Vance advises Julian to
A include video recordings of the sessions.
B focus mainly on the statistical outcomes.
C provide a live demonstration of the headset.
Questions 26–30
What decision is made about each of the following research variables?
Choose FIVE letters, A–F, and write them next to Questions 26–30.
A It will be removed entirely.
B It requires a larger sample size.
C It will be measured using a new scale.
D It needs to be collected more frequently.
E It will be compared with a control group.
F It will remain unchanged.
Research Variables
26 Patient anxiety levels
27 Session duration
28 Visual tracking data
29 Post-session feedback forms
30 Heart rate variability
Keys
21 B
22 C
23 C
24 B
25 B
26 C
27 F
28 D
29 A
30 E
Transcripts
Part 3: You will hear a student discussing a research project on Virtual Reality therapy with a tutor.
PROFESSOR VANCE: Come in, Julian. Have a seat. I’ve been looking over your initial data for the Oculus-Sync project. It’s quite a fascinating dive into VR therapy outcomes.
JULIAN: Thanks, Professor Vance. I’ve been absorbed in it. Looking at the early numbers, I thought the biggest thing we’d see would be constant technical glitches. You know, headsets freezing up. But what really blew my mind was the positive response from the elderly patients. They adapted quickly.
PROFESSOR VANCE: Yes. We didn’t see the high dropout rate we originally feared with that demographic. Now, regarding the Mind-Sphere software, I know you mentioned it’s pricey.
JULIAN: Yeah, I was worried about the cost and the lack of customizable environments. There are only three scenarios.
PROFESSOR VANCE: The funding covers licensing, so don’t worry. Three scenarios are plenty. My primary concern is that the visuals are simply too intense. It overstimulates the users, which could skew readings.
JULIAN: I see. That actually leads to the cybersickness issue. A few felt nauseous. I was thinking of excluding their data from the final report so it doesn’t mess up our averages.
PROFESSOR VANCE: We absolutely cannot alter the sample by removing them.
JULIAN: Maybe I should draw a comparison to traditional motion sickness then?
PROFESSOR VANCE: That’s been done to death. Instead, the recent literature points towards suggesting shorter VR session times as a preventative measure. Put that recommendation in your report.
JULIAN: Will do. For my workload next week, I originally planned to finalize the methodology section.
PROFESSOR VANCE: Didn’t you want to interview Dr. Aris Thorne first?
JULIAN: He isn’t available until next month. I need to push the methodology back anyway because I really need to analyze the heart rate monitor data before writing anything else.
PROFESSOR VANCE: That makes sense. Let’s talk about your final presentation.
JULIAN: I’d love to do a live demonstration of the headset for the panel.
PROFESSOR VANCE: Too risky. Technology always fails during live demos.
JULIAN: What if I include video recordings of the therapy sessions then?
PROFESSOR VANCE: Due to confidentiality, we can’t show faces. The committee is just looking for you to focus mainly on the statistical outcomes. Show them the charts.
JULIAN: Understood. We need to finalize what we’re doing with the specific research variables. First, patient anxiety levels. I used the baseline test, but results are messy. I thought about dropping it.
PROFESSOR VANCE: We can’t. It’s the core study. We will measure it using a new scale, specifically the revised Kaelen index.
JULIAN: Got it. What about the session duration? Extend it to thirty minutes?
PROFESSOR VANCE: No, alterations ruin the comparative baseline. It will remain unchanged for phase two.
JULIAN: Okay. The visual tracking data is producing massive files. Should we bring in a control group to compare it against?
PROFESSOR VANCE: Not for eye-tracking. The issue is the interval. It needs to be collected more frequently. Log every two minutes instead of five.
JULIAN: Alright. And the post-session feedback forms? Patients complain they take too long.
PROFESSOR VANCE: They are tedious. Since were doing verbal exit interviews anyway, it will be removed entirely. Scrap the forms.
JULIAN: That saves time. Finally, heart rate variability. We have solid readings. I feel we need a larger sample size, though.
PROFESSOR VANCE: Fifty participants is statistically significant, Julian. We don’t need more people. What we must do is ensure it will be compared with a control group. We need data from patients doing traditional therapy to see the difference.
